- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
EGFR+ Lung Cancer | Clinical
EGFR Exon 20-Positive NSCLC Prognosis and Challenges
November 24, 2021
Alexander Spira, MD, PhD, FACP, discusses the prognosis of patients with EGFR- exon 20 mutated non-small cell lung cancer.
Sintilimab With Bevacizumab Biosimilar and Chemotherapy Extends PFS in EGFR-NSCLC
November 22, 2021
Compared with chemotherapy alone combination of sintilimab (Tyvyt) plus a bevacizumab biosimilar injection and chemotherapy significantly improves progression-free survival in EGFR NSCLC.
Roundtable Discussion: Socinski and Participants Review Chemotherapy and EGFR Inhibition in NSCLC
November 17, 2021
During a Targeted Oncology Case-Based Roundtable event, Mark A. Socinski, MD, led a discussion about treatment of patients with EGFR-mutant non–small cell lung cancer.
High pCR Rate Shows Potential for Neoadjuvant Osimertinib in EGFR+ NSCLC
October 24, 2021
Neoadjuvant osimertinib may lead to a better mechanistic understanding of what drives incomplete response and residual disease for patients with EGFR-mutant NSCLC. according to Collin M. Blakely, MD, PhD.
Mobocertinib Elicits Efficacy in Advanced EGFR Exon 20+ NSCLC, Regardless of Prior Immunotherapy
October 20, 2021
Findings from the phase 1/2 trial of mobocertinib show clinical activity in a subset of patients with EGFR exon 20-positive non–small cell lung cancer.
Bevacizumab Biosimilar Prolongs PFS in NonSquamous NSCLC
October 18, 2021
In combination with chemotherapy and sintilimab, a bevacizumab biosimilar injection was found to increase PFS in patients with Nonsquamous NSCLC who progressed after a prior EGFR-TKI.
New Mechanisms Under Study to Overcome Osimertinib Resistance in EGFR+ NSCLC
October 18, 2021
Although osimertinib has been shown to overcome T790M-mediated mutations in the second-line setting, as with other EGFR tyrosine kinase inhibiors progression on osimertinib is inevitable.
Neoadjuvant Osimertinib May Have a Role in EGFR-Positive NSCLC
September 30, 2021
Phase 2 study results signal benefit of neoadjuvant osimertinib in patients with surgically resectable EGFR-mutant non–small cell lung cancer.
Osimertinib Plus Bevacizumab Does Not Improve PFS in EGFR-Mutated NSCLC
September 18, 2021
Osimertinib (Tagrisso) plus bevacizumab does not produce a superior progression-free survival (PFS) benefit over osimertinib monotherapy in patients with non-squamous non-small cell lung cancer harboring an EGFR mutation. However, for patients who have a history of smoking or an exon 20 deletion, the combination may prove beneficial.
Clinical Activity Shown With Mobocertinib in Advanced EGFR Exon 20 Insertion+ NSCLC, Regardless of Prior I/O
September 10, 2021
Results from a phase 1/2 study showed a high rate of objective response with mobocertinib in a subset of patients with EGFR exon 20 insertion mutation–positive non–small cell lung cancer.